Journal of International Oncology ›› 2024, Vol. 51 ›› Issue (11): 684-689.doi: 10.3760/cma.j.cn371439-20240522-00116
• Original Articles • Previous Articles Next Articles
Qiu Qi, Liu Jun(), Xie Zhibin, Deng Kelan, Wang Mengmeng
Received:
2024-05-22
Revised:
2024-09-27
Online:
2024-11-08
Published:
2024-12-26
Contact:
Liu Jun
E-mail:q02eue@163.com
Supported by:
Qiu Qi, Liu Jun, Xie Zhibin, Deng Kelan, Wang Mengmeng. Expression of long non-coding RNA TCF7 and LSINCT5 in non-small cell lung cancer tissues and the relationship with prognosis[J]. Journal of International Oncology, 2024, 51(11): 684-689.
"
临床病理特征 | 例数 | TCF7 | LSINCT5 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
高表达(n=54) | 低表达(n=54) | χ2值 | P值 | 高表达(n=55) | 低表达(n=53) | χ2值 | P值 | |||
年龄(岁) | ||||||||||
<55 | 52 | 29 | 23 | 1.34 | 0.248 | 24 | 28 | 0.91 | 0.339 | |
≥55 | 56 | 25 | 31 | 31 | 25 | |||||
性别 | ||||||||||
男 | 58 | 28 | 30 | 0.15 | 0.700 | 26 | 32 | 1.86 | 0.172 | |
女 | 50 | 26 | 24 | 29 | 21 | |||||
浸润深度(cm) | ||||||||||
≤1 | 47 | 24 | 23 | 0.04 | 0.846 | 25 | 22 | 0.17 | 0.679 | |
>1 | 61 | 30 | 31 | 30 | 31 | |||||
淋巴结转移 | ||||||||||
无 | 43 | 19 | 24 | 0.97 | 0.326 | 18 | 25 | 2.35 | 0.125 | |
有 | 65 | 35 | 30 | 37 | 28 | |||||
TNM分期 | ||||||||||
Ⅰ~Ⅱ期 | 57 | 22 | 35 | 6.28 | 0.012 | 23 | 34 | 5.40 | 0.020 | |
Ⅲ期 | 51 | 32 | 19 | 32 | 19 | |||||
组织学分级 | ||||||||||
中高分化 | 49 | 18 | 31 | 6.31 | 0.012 | 18 | 31 | 7.23 | 0.007 | |
低分化 | 59 | 36 | 23 | 37 | 22 | |||||
淋巴结状态 | ||||||||||
阴性 | 45 | 18 | 27 | 3.09 | 0.079 | 19 | 26 | 2.34 | 0.126 | |
阳性 | 63 | 36 | 27 | 36 | 27 | |||||
肿瘤最大径(cm) | ||||||||||
≤2 | 60 | 25 | 35 | 3.75 | 0.053 | 26 | 34 | 3.11 | 0.078 | |
>2 | 48 | 29 | 19 | 29 | 19 |
"
因素 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR值(95%CI) | P值 | HR值(95%CI) | P值 | ||
年龄(≥55岁/<55岁) | 1.83(0.72~4.62) | 0.203 | |||
性别(男/女) | 1.64(0.65~4.13) | 0.299 | |||
浸润深度(>1 cm/≤1 cm) | 2.77(0.53~14.46) | 0.227 | |||
淋巴结转移(有/无) | 1.55(1.11~2.17) | 0.011 | 1.57(0.68~3.62) | 0.291 | |
TNM分期(Ⅲ期/Ⅰ~Ⅱ期) | 2.15(1.32~3.48) | 0.002 | 1.25(1.03~1.53) | 0.026 | |
组织学分级(低分化/中高分化) | 1.39(1.11~1.73) | 0.004 | 1.63(1.07~2.48) | 0.023 | |
淋巴结状态(阳性/阴性) | 1.75(1.37~2.23) | <0.001 | 1.54(0.97~2.46) | 0.067 | |
肿瘤最大径(>2 cm/≤2 cm) | 1.93(1.09~3.43) | 0.024 | 1.89(0.92~3.90) | 0.084 | |
lncRNA TCF7(≥1.62/<1.62) | 1.77(1.41~2.21) | <0.001 | 1.29(1.03~1.62) | 0.025 | |
lncRNA LSINCT5(≥1.54/<1.54) | 1.54(1.21~1.97) | <0.001 | 1.48(1.14~1.93) | 0.004 |
[1] | Jianyong Z, Yanruo H, Xiaoju T, et al. Roles of lipid profiles in human non-small cell lung cancer[J]. Technol Cancer Res Treat, 2021, 20(3): 1530-1538. DOI: 10.1177/15330338211041472. |
[2] |
Wu B, Chen M, Gao M, et al. Down-regulation of lncTCF7 inhibits cell migration and invasion in colorectal cancer via inhibiting TCF7 expression[J]. Hum Cell, 2019, 32(1): 31-40. DOI: 10.1007/s13577-018-0217-y.
pmid: 30225781 |
[3] |
Zhang G, Song W. Long non-coding RNA LSINCT5 inactivates Wnt/β-catenin pathway to regulate MCF-7 cell proliferation and motility through targeting the miR-30a[J]. Ann Transl Med, 2020, 8(24): 1635. DOI: 10.21037/atm-20-7253.
pmid: 33490147 |
[4] | 支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志, 2015, 37(1): 67-78. DOI: 10.3760/cma.j.issn.0253-3766.2015.01.014. |
[5] | 中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2019版)[J]. 中华肿瘤杂志, 2020, 42(4): 257-287. DOI: 10.3760/cma.j.cn112152-20200120-00049. |
[6] |
Majem B, Nadal E, Muñoz-Pinedo C. Exploiting metabolic vulnerabilities of non small cell lung carcinoma[J]. Semin Cell Dev Biol, 2020, 98: 54-62. DOI: 10.1016/j.semcdb.2019.06.004.
pmid: 31238096 |
[7] |
Ganti AK, Klein AB, Cotarla I, et al. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US[J]. JAMA Oncol, 2021, 7(12): 1824-1832. DOI: 10.1001/jamaoncol.2021.4932.
pmid: 34673888 |
[8] | de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial[J]. N Engl J Med, 2020, 382(6): 503-513. DOI: 10.1056/NEJMoa1911793. |
[9] | Liu H, Shen Y, Xu Y, et al. lncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma, and its knockdown suppresses disease progression by regulating the miR-203-mediated Jagged1-Notch1 signaling pathway[J]. Oncol Lett, 2021, 21(5): 412. DOI: 10.3892/ol.2021.12673. |
[10] | Chen YZ, Wang JW, Meng FC, et al. LncRNATCF7 up-regulates DNMT1 mediated by HPV-18 E6 and regulates biological behavior of cervical cancer cells by inhibiting miR-155[J]. Eur Rev Med Pharmacol Sci, 2019, 23(20): 8779-8787. DOI: 10.26355/eurrev_201910_19272. |
[11] | Ding T, Deng R, Huang T. Long non-coding RNA T cell factor 7 is associated with increased disease risk and poor prognosis, and promotes cell proliferation, attenuates cell apoptosis and miR-200c expression in multiple myeloma[J]. Oncol Lett, 2021, 21(2): 129. DOI: 10.3892/ol.2020.12390. |
[12] | 袁前超, 郑志阳, 齐宇. LncRNA TCF7调节JAK/STAT信号通路对肺癌细胞增殖的影响[J]. 实用癌症杂志, 2022, 37(2): 181-185. DOI: 10.3969/j.issn.1001-5930.2022.02.002. |
[13] |
Liu B, Cao W, Ma H. Knockdown of lncRNA LSINCT5 suppresses growth and metastasis of human glioma cells via up-regulating miR-451[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 2507-2515. DOI: 10.1080/21691401.2019.1626404.
pmid: 31213092 |
[14] | 熊玮, 刘慧敏, 刘平, 等. lncRNA LSINCT5通过miR-451调控肺癌细胞侵袭、迁移及顺铂敏感性的实验研究[J]. 中国免疫学杂志, 2022, 38(11): 1349-1354. DOI: 10.3969/j.issn.1000-484X.2022.11.012. |
[15] | Yang W, Yang X, Li Q, et al. Long stress-induced non-coding transcript 5: a promising therapeutic target for cancer treatment[J]. Adv Clin Exp Med, 2023, 32(1): 97-106. DOI: 10.17219/acem/152705. |
[16] | Jiang H, Li Y, Li J, et al. Long noncoding RNA LSINCT5 promotes endometrial carcinoma cell proliferation, cycle, and invasion by promoting the Wnt/β-catenin signaling pathway via HMGA2[J]. Ther Adv Med Oncol, 2019, 11: 1758835919874649. DOI: 10.1177/1758835919874649. |
[17] | Jing L, Lin J, Zhao Y, et al. Long noncoding RNA LSINCT5 is upregulated and promotes the progression of esophageal squamous cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2019, 23(12): 5195-5205. DOI: 10.26355/eurrev_201906_18184. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||